Sedulo Group — Recent Moves (15 tracked, last 90 days)

Sedulo Group is a competitive-intelligence and strategy consultancy that has been unusually active over the tracking window, with 15 moves observed in roughly six weeks. The pattern points to a firm that is not just advising on market dynamics, but aggressively productizing its point of view through frameworks, case studies, and industry events.

For competitive-intelligence professionals, the signal is that Sedulo Group is pushing deeper into life sciences, pricing, and decision support — and packaging its expertise into repeatable assets rather than relying on bespoke engagements alone. Tracking its recent moves reveals a company that is trying to set the agenda, not just respond to it.

Life sciences and pharma are the center of gravity: Sedulo Group is visibly doubling down on life sciences, from facilitating pharmaceutical workshops for competitive scenario planning in early June to opening a 2026 Life Sciences Competitive Intelligence Survey and landing lead sponsorship of Pharma CI USA 2026 in late July. A July case study on pharmaceutical BD scouting reinforces that it wants to own a specific niche: competitive intelligence for pharma commercial and business development decisions.

Productization is accelerating: The firm is rapidly converting its consulting know-how into off-the-shelf tools. It added new strategic decision frameworks to a digital template library in mid-June, launched a framework for B2B deal desk implementation in late July, and is promoting a 'Gold' PPT framework for executive-ready intelligence reporting. This suggests a strategic shift from pure advisory toward scalable intellectual property.

Pricing and go-to-market intelligence are flagship themes: Three moves point to a commercial-optimization angle: a June feature on price realization and software pricing strategies, promotion of B2B mystery shopping for live sales intelligence, and deployment of real-time oncology sales monitoring and HRM GTM case studies. The mix of pricing, sales intelligence, and GTM analytics suggests Sedulo is positioning itself as a bridge between CI and revenue outcomes.

Credibility building is a deliberate play: Sedulo is investing heavily in validation and content distribution. Its CI framework received high-authority validation in a Clarivate Pharma feature, it launched "The Intelligence Exchange" newsletter for executive decision support, and it released multiple case studies across sectors. These moves work together to create an authoritative, visible brand that can sustain premium positioning.

What to watch: The most important near-term signal will be how Sedulo productizes its 2026 Life Sciences survey results and whether the B2B deal desk framework becomes a flagship offering. If the case study cadence continues across adjacent verticals, expect the company to push even harder into benchmarking and cross-industry templates.